The isolation and characterisation of antiplatelet antibodies.
The isolation and characterisation of antiplatelet antibodies in autoimmune thrombocytopenia purpura patients (ITP) is described. Autoimmune thrombocytopenia purpura is an autoimmune disease, clinically defined by low platelet counts, normal or increased megakaryocytopoiesis and antiplatelet antibodies in serum. This study used phage display to isolate Fab antiplatelet antibodies to study the structure-function relationships of pathogenic antibodies in ITP. Out of six randomly selected colonies, four colonies reacted strongly with whole platelets in enzyme-linked immunosorbent assay (ELISA). Sequence analysis showed that all four colonies had the same DNA sequence and were the same antibody. Results of Western blotting against non-reduced human platelet lysate showed that the Fab reacted with platelet proteins with apparent molecular weights of 116, 92 and 39 kD. Furthermore, Western blotting assay against purified membrane glycoprotein IIIa demonstrated reactivity against a band with a molecular weight of 92 kD. Results from Western blotting against platelet lysate and pure platelet glycoprotein confirmed the Fab fragment recognised the platelet glycoprotein IIIa. Three out of the four phage colonies produced soluble Fab, which demonstrated reactivity against platelet autoantigens in ELISA. Further sequence analysis showed that the Fab was somatically mutated suggesting antigen drive and therefore T-cell assistance was important in the development of this antibody. One of the somatic mutations introduced an RSD amino acid sequence in the complementary determining region 1 (CDR1) of the light chain, which may mimic the RGD motif of fibrinogen which binds integrin GPIIb/IIIa. This raises the possibility that somatic mutation and antigen drive have produced a pathogenic autoantibody.
Hamidpour
Mohsen
M
Paramedical College, Shahid Beheshti University of Medical Sciences, Quds Square, Darband Avenue, Tehran, Iran.
Behrendt
Mark
M
Griffiths
Bridget
B
Partridge
Lynda
L
Lindsey
Nigel
N
D000918:Antibody Specificity / Q000235:genetics* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000235:genetics* / Q000276:immunology; D001324:Autoantigens / Q000097:blood / Q000235:genetics / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology*; D003001:Cloning, Molecular / Q000379:methods; D022801:Complementarity Determining Regions / Q000097:blood / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood / Q000235:genetics / Q000276:immunology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics / Q000276:immunology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000235:genetics* / Q000276:immunology; D017422:Sequence Analysis, DNA / Q000379:methods; D027041:Somatic Hypermutation, Immunoglobulin / Q000235:genetics* / Q000276:immunology; D013329:Structure-Activity Relationship; D013601:T-Lymphocytes / Q000276:immunology; D034061:Thrombopoiesis / Q000276:immunology
D001323:Autoantibodies; D001324:Autoantigens; D022801:Complementarity Determining Regions; D007147:Immunoglobulin Light Chains; D019039:Platelet Glycoprotein GPIIb-IIIa Complex